Myriad Genetics (MYGN) Other Non-Current Liabilities (2010 - 2026)

Myriad Genetics (MYGN) has reported Other Non-Current Liabilities for 17 consecutive years, with $1.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non-Current Liabilities fell 15.0% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (down 15.0% YoY), while the FY2025 annual figure was $1.9 million, down 13.64% from the prior year.
• Other Non-Current Liabilities eased to $1.7 million in Q1 2026 per MYGN's latest filing, from $1.9 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $48.1 million in Q4 2023 and bottomed at $1.7 million in Q3 2025.
• Historically, Other Non-Current Liabilities has averaged $18.5 million across 5 years, with a median of $11.4 million in 2023.
• On a YoY basis, Other Non-Current Liabilities climbed as much as 253.04% in 2024 and fell as far as 95.43% in 2024.
• Myriad Genetics' Other Non-Current Liabilities stood at $43.9 million in 2022, then climbed by 9.57% to $48.1 million in 2023, then slumped by 95.43% to $2.2 million in 2024, then decreased by 13.64% to $1.9 million in 2025, then slipped by 10.53% to $1.7 million in 2026.
• Business Quant data shows MYGN's Other Non-Current Liabilities at $1.7 million in Q1 2026, $1.9 million in Q4 2025, and $1.7 million in Q3 2025.